30 completed. 30 Phase 2, 8 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 30 |
| Phase 3 | 8 | Completed 8 |
| Phase 1 | 1 | Completed 1 |
Follow Polymyositis: new trials by email Literature Review of Polymyositis trials Research Report on Polymyositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis Brepocitinib - Dermatomyositis, Dermatomyositis, Adult Type | Phase 2 | Completed | Priovant Therapeutics, Inc. | 5 | 2024-08-28 | 2025-05-20 |
| A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants With Dermatomyositis (DM) or Anti-synthetase Inflammatory Myositis (ASIM) Daxdilimab, Placebo - Idiopathic Inflammatory Myositis | Phase 2 | Completed | Amgen | 12 | 2023-12-04 | 2026-08-25 |
| A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis GLPG3667, Placebo - Dermatomyositis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 40 | 2023-02-27 | 2026-05-14 |
| Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) Baricitinib, pharmacokinetics study, dosage of cytokines - Juvenile Dermatomyositis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2022-11-10 | 2026-04-23 |
| A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. EFG PH20 SC, PBO - Active Idiopathic Inflammatory Myopathy, Myositis | Phase 2 / Phase 3 | Completed | argenx | 265 | 2022-10-12 | 2026-09-21 |
| An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study Anti-Beta Interferon (PF-06823859) - Dermatomyositis | Phase 2 | Completed | Pfizer | 24 | 2021-12-20 | 2025-02-06 |
| Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis PN-101 - Polymyositis, Dermatomyositis | Phase 1 / Phase 2 | Completed | Paean Biotechnology Inc. | 9 | 2021-12-15 | 2024-04-03 |
| Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. KZR-616 - Polymyositis, Dermatomyositis | Phase 2 | Completed | Kezar Life Sciences, Inc. | 18 | 2020-11-04 | 2025-11-19 |
| A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis KZR-616, Placebo - Polymyositis, Dermatomyositis | Phase 2 | Completed | Kezar Life Sciences, Inc. | 25 | 2020-01-14 | 2025-11-19 |
| Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Apremilast 30mg - Dermatomyositis, Adult Type | Phase 2 | Completed | Tulane University | 8 | 2018-06-12 | 2023-03-03 |
| A Study In Adults With Moderate To Severe Dermatomyositis PF-06823859 low, Placebo Arm, PF-06823859 high - Dermatomyositis | Phase 2 | Completed | Pfizer | 75 | 2018-01-23 | 2023-09-14 |
| Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Sodium Thiosulfate - Dermatomyositis, Idiopathic Inflammatory Myopathies | Phase 2 / Phase 3 | Completed | National Institute of Environmental Health Sciences (NIEHS) | 15 | 2017-10-05 | 2024-11-26 |
| Trial of IMO-8400 in Adult Patients With Dermatomyositis IMO-8400 Dose Group 1, IMO-8400 Dose Group 2, Placebo - Dermatomyositis | Phase 2 | Completed | Idera Pharmaceuticals, Inc. | 30 | 2015-11-01 | 2019-10-10 |
| Belimumab in Idiopathic Inflammatory Myositis Belimumab, Placebo - Myositis | Phase 2 / Phase 3 | Completed | Northwell Health | 17 | 2015-01-01 | 2024-02-09 |
| Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Rituximab, Cyclophosphamide - Interstitial Lung Disease, Scleroderma | Phase 2 / Phase 3 | Completed | Royal Brompton & Harefield NHS Foundation Trust | 104 | 2014-11-01 | 2021-10-07 |
| Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis tocilizumab, placebo - Dermatomyositis, Polymyositis | Phase 2 | Completed | Chester Oddis | 36 | 2014-10-01 | 2020-10-30 |
| Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Adrenocorticotropic Hormone Gel - Dermatomyositis, Polymyositis | Phase 2 | Completed | Rohit Aggarwal, MD | 12 | 2013-09-01 | 2017-09-01 |
| Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Fractionated Carbon Dioxide (FCO2) Laser, Sodium thiosulfate - Calcinosis | Phase 2 | Completed | Alison Ehrlich | 3 | 2012-08-01 | 2017-11-29 |
| Abatacept Treatment in Polymyositis and Dermatomyositis Abatacept Active Treatment, Abatacept Delayed-Onset Treatment - Polymyositis, Dermatomyositis | Phase 2 | Completed | Karolinska Institutet | 20 | 2011-01-01 | 2020-11-06 |
| Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Active rehabilitation - Dermatomyositis, Polymyositis | Phase 2 | Completed | University Hospital, Lille | 80 | 2008-03-01 | 2025-12-22 |
Showing 20 of 30. Sign in to see all of them.
Dermatomyositis (29) · Myositis (11) · Myositis, Inclusion Body (3) · Calcinosis (2) · Connective Tissue Diseases (2) · Lung Diseases, Interstitial (2) · Mixed Connective Tissue Disease (2) · Muscular Diseases (2) · Musculoskeletal Diseases (2) · Vasculitis (2) · Antisynthetase syndrome (1) · Arthritis, Juvenile (1) · Cardiovascular Diseases (1) · Crohn Disease (1)
Nervous System Diseases (30) · Neuromuscular Diseases (30) · Skin Diseases (29) · Skin and Connective Tissue Diseases (29) · Muscular Diseases (28) · Musculoskeletal Diseases (28) · Connective Tissue Diseases (27) · Myositis (19) · Pathological Conditions, Signs and Symptoms (4) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Pathologic Processes (3) · Respiratory Tract Diseases (3) · Calcium Metabolism Disorders (2)
Infliximab (2) · KZR-616 (2) · Rituximab (2) · sodium thiosulfate (2) · Abatacept (1) · Alendronate (1) · Cyclophosphamide (1) · Interleukin 1 Receptor Antagonist Protein (1) · Lasers (1) · Methimazole (1) · Methylprednisolone (1) · Prednisolone (1) · Pregnancy Tests (1) · Tacrolimus (1) · apremilast (1)
Karolinska Institutet (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Kezar Life Sciences, Inc. (2) · Pfizer (2) · Alison Ehrlich (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Boston Children's Hospital (1) · Chester Oddis (1) · Idera Pharmaceuticals, Inc. (1) · Lakefront Biotherapeutics NV (1) · National Institute of Environmental Health Sciences (NIEHS) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Northwell Health (1) · Northwestern University (1)
United States (21) · Czechia (7) · Spain (5) · United Kingdom (5) · France (4) · Germany (4) · Hungary (4) · Poland (4) · Sweden (4) · Mexico (3) · Argentina (2) · Belgium (2) · Canada (2) · Italy (2) · Japan (2)
Adam I Schiffenbauer, M.D. (2) · Chester V. Oddis, MD (2) · Ingrid E Lundberg, MD, PhD (2) · Alison Ehrlich, MD (1) · Andre Thevenon, Professor (1) · Andrea Morris, MD (1) · Ann M. Reed, MD (1) · Carole Bitar, MD (1) · Catherine Gordon, MD (1) · Daehyun Yoo, MD (1) · Eunyoung Lee, MD (1) · Galina Marder, MD (1)
PMID 42542380, PMID 23124935, PMID 27789240, PMID 28619061, PMID 29174792, PMID 29237618, PMID 31539061, PMID 36197661, PMID 36375479, PMID 37326854, PMID 37941470, PMID 38172601, PMID 38805213, PMID 39798982, PMID 41874840, PMID 42273013
2009 (1), R01AR061298 (1)